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Introduction 
Pseudomonas aeruginosa (P. aeruginosa) is a non-fastidious, 
motile, oxidase-positive non-fermenting Gram-negative 
bacterial pathogen (belonging to the rRNA group I. 
among non-fermenters, based on the genomic classifi-
cation of Palleroni) (Palleroni 1993; Palleroni 2010). P. 
aeruginosa is ubiquitous in nature (in soil, on plants, and 
in aquatic environments, in addition to being trans-
mitted by birds and smaller mammals as reservoirs) 
and it is also frequently found in healthcare-associated 
environments (e.g., persisting in water taps and other 
inanimate surfaces, irrigation fluids, respiratory tubes, 
surgical theaters and on medical equipment, spreading 
via aerosol-formation) as a colonizer on patients (8-20% 
of infections are preceded by colonization of the relevant 
anatomical regions) (Blanc et al. 2007; Gumey et al. 2020; 
Hall et al. 2016). This pathogen may be a causative agent 
in severe, life-threatening infections (especially in im-
munocompromised individuals or in patients treated in 
intensive care units), including pneumonia (Szabó et al. 
2005), bacteremia/sepsis (Behzadi et al. 2021), skin and 
soft tissue infections associated with burns and surgeries 
(Maenni et al. 2017), otitis externa, keratitis (Cannas et al. 
2015) and urinary tract infections (Gajdács et al. 2020). 
In addition, P. aeruginosa may be an important colonizer 
in the airways of patients with cystic fibrosis and chronic 
obstructive pulmonary disease (COPD), leading to acute 
exacerbations and decreased quality of life (Clark et al. 
2015; Shariff and Beri 2017). 
P. aeruginosa is characterized by having a large (5.5-
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Pseudomonas aeruginosa (P. aeruginosa) is ubiquitous in nature, and 
may be a causative agent in severe, life-threatening infections. In >60% of cases, β-lactam 
antibiotics are used in the therapy of P. aeruginosa infections, therefore the emergence 
of carbapenem-resistant P. aeruginosa (CRPA) is a signifi cant clinical concern. In this 
study, phenotypic methods were used to characterize fi fty-four (n = 54) P. aeruginosa 
isolates, which were included based on their suspected non-susceptibility to merope-
nem. Minimum inhibitory concentrations (MICs) of meropenem, ceftazidime, cefepime, 
ciprofl oxacin, gentamicin, were determined using E-tests, while colistin MICs were de-
termined using broth microdilution. The isolates were subjected to the modifi ed Hodge 
test (MHT), the modifi ed carbapenem-inactivation method (mCIM) and the imipenem/
EDTA combined disk test (CDT). AmpC and effl  ux pump overexpression was studied 
using agar plates containing cloxacillin and phenylalanine-arginine β-naphthylamide 
(PAβN), respectively. Assessment of biofi lm-formation was carried out using the crystal 
violet tube-adherence method. 38.9% of the strains showed meropenem MICs in the 
resistant range (>8 mg/L). Effl  ux-pump overexpression and AmpC-hyperproduction was 
seen in 44.4% and 35.2% of isolates, respectively. 88.8% of the isolates were character-
ized as strong biofi lm-producers. On the other hand, the presence of carbapenemases 
was suspected in a minority (16.7%) of tested isolates. As safe and eff ective therapeutic 
options in carbapenem-resistant Gram-negative infections are severely limited, charac-
terization of these isolates using phenotypic and molecular-based methods is important 
to provide insights into the epidemiological features of these pathogens.

























7 Mb) genome a with pronounced genomic plasticity, 
including many regulatory genes, affecting motility, ef-
flux proteins, metabolic pathways and the expression of 
virulence factors and antibiotic resistance determinants 
(Algammal et al. 2020; Behzadi and Behzadi 2011; Behzadi 
et al. 2021). The heterogeneity of the P. aeruginosa genome 
may be further increased through horizontal gene transfer, 
by the introduction of various mobile genetic elements 
(Suenaga et al. 2017). A plethora of virulence-determinants 
have been described in P. aeruginosa, including secreted 
virulence factors such as pigments, exotoxins, proteases 
and other enzymes (e.g., lipases, alkaline protease, elastase 
A, DNase), secretion systems (type I-VI) and an exopolysac-
charide biofilm; in addition, bacterial cell wall-associated 
structural components, including lipopolysaccharide 
(LPS), flagella (for swarming, swimming, and twitching 
motility), pili, adhesins and lectins (Barrak et al. 2020; 
Behzadi et al. 2021; Hogardt and Heesemann 2013; Jain 
et al. 2012). 
In the era of multidrug resistant (MDR) pathogens, 
the therapy of P. aeruginosa infections is becoming in-
creasingly difficult (Bassetti et al. 2018; Füzi et al. 2017). 
To start with, this pathogen is intrinsically resistant to 
aminopenicillin/β-lactamase-inhibitor combinations, 
I–II. generation cephalosporins and orally administered 
III. generation cephalosporins, rifampin, tetracycline, 
chloramphenicol, trimethoprim-sulfamethoxazole and 
macrolides (Bassetti et al. 2018; Bonomo and Szabó 2006). 
Thus, the therapy of pseudomonad infections heavily 
relies on a select group of antibiotics, including III. and 
IV. generation parenterally administered cephalosporins, 
carbapenems, fluoroquinolones, aminoglycosides and co-
listin. Nevertheless, in >60% of cases, β-lactam antibiotics 
are used in the therapy of P. aeruginosa infections, therefore 
resistance against these agents (especially carbapenems) 
is a significant clinical concern (Algammal et al. 2020; 
Bassetti et al. 2018; Behzadi et al. 2021). The emergence 
of carbapenem-resistant P. aeruginosa (CRPA) may oc-
cur through a combination of resistance mechanisms, 
including decreased membrane permeability and porin 
loss (e.g., OprD, OprF porin mutants), overexpression 
of efflux pumps (MexAB-OprM and MexCD-OprJ), 
changes in penicillin-binding proteins (PBPs) and the 
production of either chromosomally-encoded or plas-
mid-mediated β-lactamase enzymes (carbapenemases) 
capable of hydrolyzing these drugs (Hassuna et al. 2020; 
Mirzaei et al. 2020). While in some non-fermenters pos-
sess chromosomally-mediated β-lactamases are the norm 
(e.g., L1 and L2 metallo-β-lactamases in Stenotrophomonas 
malthophilia), carbapenemases encoded on mobile genetic 
present a serious public health issue, as they are capable 
of widespread dissemination (Gajdács and Urbán 2019; 
Poole 2011); additionally, these genetic elements often 
include a wide range of other resistance determinants. 
The accumulation of intrinsic and plasmid-mediated 
resistance in P. aeruginosa may lead to the emergence of 
MDR, extensively-drug resistant (XDR) and pandrug-
resistant (PDR) isolates (Gajdács 2019; Ranjan et al. 2020). 
The characterization of carbapenem-resistant Gram-
negative isolates using phenotypic and molecular-based 
methods is important to provide insights into the epide-
miological features of these pathogens, both locally and 
internationally (Eszik et al. 2016; Mirzaei et al. 2020; 
Nordmann and Poirel 2019). The aim of our present 
laboratory-based study was to characterize a selection of 




A total of fifty-four (n = 54) P. aeruginosa isolates were 
included in this study, which were kindly provided by 
various Hungarian and Italian hospitals, originating from 
different clinical materials. Inclusion of these strains was 
based on the non-susceptibility criteria to meropenem 
(MER) used in routine clinical microbiology, defined 
by EUCAST (European Committee on Antimicrobial 
Susceptibility Testing) guidelines v.9.0 (meropenem disk 
diameter 23-18 mm: intermediate, <19 mm: resistant) 
(https://www.eucast.org/clinical_breakpoints/). Identi-
fication of the isolates was carried out based on classical 
phenotypic and biochemical panel-based methods (Leber 
2016). All isolates included in the study were re-identified 
as P. aeruginosa before further assays. For shorter time 
periods (<1 month), the bacterial strains were maintained 
on blood agar with continuous passage. For longer periods, 
the strains were kept in a -80 °C freezer, in a 1:4 mixture 
of 85% glycerol and liquid Luria-Bertani medium. During 
our experiments P. aeruginosa ATCC 27853 was used as 
a control strain.
Minimum inhibitory concentrations (MICs) of merope-
nem and ancillary antibiotics
MICs of MER, ceftazidime (CEF), cefepime (CFP), gen-
tamicin (GEN) and ciprofloxacin (CIP) were determined 
by E-tests (Liofilchem, Roseto degli Abruzzi, Italy) on 
Mueller-Hinton agar plates (Oxoid, Basingstoke, UK). 
MIC determination for colistin (COL) was carried out 
using the broth microdilution method in cation-adjusted 
Mueller-Hinton broth (MERLIN Diagnostika, Berlin, 
Germany) (Gajdács et al. 2020). The interpretation of the 
results was based on the European Committee on Anti-




Phenotypic detection of AmpC overexpression 
Overexpression of AmpC β-lactamase enzymes was de-
tected by an agar plate method, where the agar base was 
supplemented with cloxacillin (250 µg/mL), as cloxacillin 
inhibits the effects of AmpC β-lactamases (Khalili et al. 
2019). A two-fold decrease in CEF MICs in the presence 
of cloxacillin, compared to MICs without cloxacillin, 
was considered as positivity for AmpC overexpression 
(Akhi et al. 2018).
Phenotypic detection of carbapenemase and metallo-β-
lactamase (MBL) production
To establish carbapenemase-production in the isolates 
included in the study, the isolates were subjected to the 
modified Hodge test (MHT) and the modified carbapen-
em-inactivation method (mCIM), optimized for P. aerugi-
nosa, as previously described (Chou et al. 2020; Pitout et 
al. 2008; Rao et al. 2019). In both assays, MER disks (10 
µg; Oxoid, Basingstoke, UK) were utilized and Escherichia 
coli ATCC 25922 was used as an indicator organism.
Metallo-β-lactamase (MBL) production was tested 
using the imipenem/EDTA combined disk test (CDT), as 
described previously (Makharita et al. 2020). In prepara-
tion to this assay, imipenem/EDTA disks were prepared 
by adding 750 μg of a sterile 0.5 M EDTA solution to a 
10 μg imipenem disk, then disks were dried in a 37 оC 
incubator. The assay was considered positive if the inhi-
bition zone diameter (≥17 mm) of the imipenem/EDTA 
disk increased compared to the imipenem disk alone 
(Makharita et al. 2020).
Phenotypic detection of efflux pump overexpression
The effect of phenylalanine-arginine β-naphthylamide 
(PAβN; a compound with well-known efflux pump inhibi-
tory activity) on the MICs of MER was detected using 
the agar dilution method described previously (Khalili 
et al. 2019). During the experiments, the concentration 
of PAβN was 40 µg/mL in the agar base. A two-fold de-
crease in MER MICs in the presence of PAβN, compared 
to the MIC values without the inhibitor, was considered 
as positivity for efflux pump overexpression (Khalili et 
al. 2019; Gajdács 2020).
Detection of biofilm-production by the tube-adherence 
method
Assessment of biofilm-formation was carried out in the 
tube-adherence method described previously (Dumaru et 
al. 2019; Senobar Tahaei et al. 2021). In short, glass tubes 
containing 1 mL of sterile trypticase soy broth (bioMéri-
eux, Marcy-l’Étoile, France) were inoculated with 1 µL 
of the overnight culture of a respective bacterial strains. 
Respective tubes were then incubated statically for 24 h 
at 37 °C. Verification of planktonic growth was observed 
visually. After the incubation period, the supernatant 
was then discarded, the adhered cells were rinsed three 
times with phosphate buffer saline (PBS; Sigma-Aldrich; 
Budapest, Hungary) and the tubes were patted dry on a 
paper towel. The contents of the tubes were treated with 
a 1 mL solution of 0.1% crystal violet (CV; Sigma-Aldrich; 
Budapest, Hungary) to stain the adhered biomass; the 
tubes were incubated for 3 h at room temperature with 
the staining solution. The CV solution was then discarded, 
and the tubes were again rinsed three times with PBS 
and the tubes were patted dry on a paper towel. Biofilm-
formation was observed visually; based on the appearance 
of visible biofilm lining at the bottom and on wall of the 
glass tubes, the strains were classified as non-biofilm 
producers (-), weak biofilm producers (-/+) and strong 
biofilm producers (+) (Dumaru et al. 2019). All experi-
ments were evaluated by two independent researchers.
Statistical analysis
Descriptive statistical analysis (including means and 
percentages to characterize data) was performed using 
Microsoft Excel 2013 (Microsoft Corp.; Redmond, WA, 
USA).
Ethical considerations
The study was conducted in accordance with the Decla-
ration of Helsinki and national and institutional ethical 
standards. Ethical approval for the study protocol was 
obtained from the Human Institutional and Regional 
Biomedical Research Ethics Committee, University of 
Szeged (registration number: 140/2021-SZTE [5019]).
Results 
MICs of the tested antibiotics, phenotypic detection of 
AmpC overexpression 
The MICs of the tested antibiotics, including MIC50, MIC90 
values, MIC ranges and the percentage of resistant isolates 
are presented in Table 1. The highest levels of resistance 
were observed for CIP (n = 42, 77.8%), followed by CEF (n = 
36, 66.7%) and CFP (n = 33, 61.1%). All tested isolates were 
susceptible to COL, with MIC values ranging between 
0.064 and 2 mg/L. Based on EUCAST breakpoints, n = 
21 (38.9%) of isolates showed MICs above the resistance 
breakpoint for MER (8 mg/L), with MICs ranging between 
0.5 and 64 mg/L. Among the tested P. aeruginosa isolates, 
overexpressions of AmpC-enzymes were observed in n 
= 19 (35.2%), where a two-fold decrease in the CEF MICs 
was seen in the presence of cloxacillin.
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Phenotypic detection of carbapenemase, MBL produc-
tion and efflux pump overexpression
To detect the presence of carbapenemases, two distinct 
phenotypic methods were utilized: n = 11 (20.4%) isolates 
presented with positive results in the modified Hodge test 
(MHT), while this number was n = 9 (16.7%) during the 
modified carbapenem-inactivation (mCIM) test. If we 
consider the results of the antibiotic susceptibility test-
ing (MER MIC > 8 mg/L) as a reference in our study, the 
agreement between the results of the MIC determination 
and the results of the MHT and mCIM tests were 52.3% 
and 42.9%, respectively. MBL-production was noted in n = 
3 (5.6%) of isolates, using the imipenem/EDTA combined 
disk test (CDT). Efflux pump-overexpression (based on 
the PAβN screening agar) was detected in n = 24 (44.4%) of 
isolates. In the case of n = 3 isolates, efflux pump-overex-
pression and MHT/mCIM-positivity were detected, while 
for n = 2 isolates, AmpC-hyperproduction and MHT/
mCIM-positivity was seen; for n=6 isolates, high MER 
MICs were seen with efflux pump-overexpression and 
AmpC-hyperproduction and negative MHT/mCIM tests.
Biofilm production in the tested isolates
Majority (n = 48, 88.8%) of the tested isolates were strong 
(+) biofilm producers in the CV tube-based assay, while 
n = 4 (7.4%) were weak biofilm producers (-/+) and two 
(3.7%) did not form biofilm (-). 
Discussion 
Antimicrobial resistance has emerged as a significant pub-
lic health issue in the 21st century, mainly stemming from 
the imprudent use of these agents in both community-
based and inpatient settings, which has exacerbated the 
prevalence of resistant bacterial isolates (Aslam et al. 2020; 
Gajdács et al. 2018; Hemlata and Tiwari 2017); it has been 
suggested that infections caused by MDR bacteria may be 
one of the major causes of mortality by 2050 (Gajdács et al. 
2021; Shallcross et al. 2015). Drug-resistant P. aeruginosa 
is a significant nosocomial pathogen with the potential 
to cause serious, difficult-to-treat infections (Kadri et al. 
2018). For this reason, it is unsurprising that P. aerugi-
nosa has been included among the so-called „ESKAPE” 
pathogens (designated by the Infectious Diseases Society 
of America; IDSA), listing the MDR bacteria that are of 
particular concern for healthcare (Pachori et al. 2016; 
Rice 2008). From a clinical standpoint, infections caused 
by CRPA present an important therapeutic problem, as 
even with the introduction of some novel antimicrobials 
(e.g., β-lactam-β-lactamase combinations, neoglycosides), 
there are limited number of safe and effective therapeu-
tic alternatives remaining (Hu et al. 2019). Based on the 
data of the US Centers for Disease Control (CDC), the 
prevalence of CRPA was around ~12%, corresponding 
to ~51 000 nosocomial infections per year (Nordmann 
and Poirel 2019); while based on the data of the European 
Antimicrobial Resistance Surveillance Network (EARS-
Net) for 2017, the population-weighted mean prevalence 
of CRPA in invasive isolates was 17.4% (lowest in Iceland 
[0%], highest in Romania 63.4%]) (ECDC 2019). 
Carbapenem resistance in Pseudomonas more com-
monly occurs due to alternations in the membrane per-
meability (i.e. porin deficiency) and the overexpression 
of efflux pumps, while the production of carbapenemases 
is observed less frequently, especially when compared 
to the members of Enterobacteriaceae and Acinetobacter 
spp. (Nordmann and Poirel 2019). Initially, metallo-β-
lactamases were characteristic for Pseudomonas spp.; in fact, 
both IMP (active-on-imipenem) and VIM-type (Verona 
intergon-encoded MBL) enzymes were first described in 
pseudomonads (Lauretti et al. 1999; Watanabe et al. 1991). 
Since then, the presence of many other carbapenemases 
(including the Klebsiella pneumoniae carbapenemase [KPC], 
and the New Delhi metallo-beta-lactamase [NDM]) were 
reported in CRPA isolates (Halat and Moubareck 2020; 
Nordmann and Poirel 2019). In our present study, a 
collection of P. aeruginosa isolates – suspected of being 
CRPA – were included and their characterization was 
carried out using various phenotypic assays. Among the 
isolates, 38.9% of the strains showed MER MICs in the 
resistant range, while apart from COL (which showed 
100% susceptibility), resistance rates were high (>50%) 
against the other tested antibiotics as well. Similarly to 
Resistant strains (n, %) MIC range (mg/L) MIC50 (mg/L) MIC90 (mg/L)
Meropenem (MER) 21 (38.9%) 0.5-64 4 16
Ceftazidime (CEF) 36 (66.7%) 0.5-256 8 64
Cefepime (CFP) 33 (61.1%) 0.5-256 8 64
Gentamicin (GEN) 28 (51.9%) 0.25-128 2 16
Ciprofloxacin (CIP) 42 (77.8%) 0.128-16 1 4
Colistin (COL) 0 (0%) 0.064-2 0.128 0.5
Table 1. MIC values of meropenem and ancillary antibiotics on the tested bacterial strains.
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other reports in the literature, carbapenemase-detection 
methods were positive in a lower number of isolates, i.e. 
20.4% for MHT and 16.7% for mCIM, whereas the pres-
ence MBL was suggested in only 5.6%, respectively. On 
the other hand, the prevalence of efflux pump overexpres-
sion was seen in a much higher rate, in 44.4% of isolates. 
Another common characteristic of clinical P. aeruginosa 
isolates is the production of a protective biofilm, which 
was verified in vitro in 88.8% of our isolates. 
Between 2003 and 2005, the first outbreaks and the 
spread of MBL-producing Pseudomonas sp. was reported 
in Hungary, corresponding to two distinct groups of 
isolates based on serotyping (O11 and O12, respectively) 
with the carriage of VIM-4 (Libisch et al. 2006). Most 
of these isolates originated from either urine or tracheal 
aspirate samples and most of them had high MICs cor-
responding to imipenem (>256 mg/L) and MER (>32 
mg/L) (Libisch et al. 2006). The first detection of a PER-1 
and VIM-2-producing P. aeruginosa isolate was reported 
in 2008, which was associated with a Hungarian patient 
who was initially hospitalized in Egypt (Szabó et al. 
2008); in this clinical case, three distinct P. aeruginosa 
strains were detected, one resistant to antipseudomonal 
cephalosporins (with MICs>256 mg/L), one resistant 
to imipenem only (MIC>32 mg/L) and one presenting 
with high-level resistance against imipenem (MIC>256 
mg/L) and MER (MIC>32 mg/L) (Szabó et al. 2008). 
In an effort to provide the most effective therapy for 
patients affected by invasive P. aeruginosa infections, a 
Monte Carlo simulation was performed using the sus-
ceptibility data from Hungarian P. aeruginosa isolates: 
the results suggest that due to the worsening rates of 
resistance, as increasing doses, frequencies or infusion 
times, in addition to combination antimicrobial therapy 
may be relevant in the empiric therapy of P. aeruginosa in 
Hungary (Ludwig et al. 2006). Based on the surveillance 
data of the Hungarian National Public Health Centre, 
bloodstream infections were among the more common 
nosocomial infections caused by P. aeruginosa in recent 
years (Epi-Net 2021). A study group in Hungary has 
published the occurrence of MDR P. aeruginosa found 
in environmental sites contaminated by hydrocarbons 
between the period of 2002-2007; carbapenem-resistance 
was noted in 33% of isolates (Kaszab et al. 2010). The same 
study group has also recently reported ceftriaxone and 
imipenem resistance in 25.0% of tested environmental P. 
aeruginosa isolates; in addition, five out of the 44 isolates 
originating from sources as groundwater, soil or compost 
showed close genetic relatedness to clinically relevant 
pulse-field types based on pulse-field gel electrophoresis 
(PFGE) (Kaszab et al. 2019). In a laboratory-based study, n 
= 250 carbapenem-resistant P. aeruginosa were surveyed 
for their susceptibilities against ceftazidime-avibactam 
(C/A) and ceftolozane–tazobactam (C/T), in addition 
to a phenotypic-genotypic study for carbapenemase-
production: prevalence of resistance to C/A and C/T was 
33.6% and 32.4%, respectively; isolates producing positive 
CIM-tests were VIM (80%) or NDM (11%) producers 
(O’Neall et al. 2020). This study has concluded that in 
case of a negative CIM-test for a relevant carbapenem 
non-susceptible P. aeruginosa isolate, either C/A or C/T 
may be an effective therapeutic choice (O’Neall et al. 
2020). A study involving n = 57 carbapenem-resistant, but 
cephalosporin susceptible (Car-R/Ceph-S) P. aeruginosa 
isolates originating from urinary tract infections has 
highlighted the role of efflux pump overexpression and 
overproduction of AmpC β-lactamases in the development 
of the carbapenem-resistant phenotype; the study has 
also highlighted that – although rare – these isolates may 
constitute a viable target for colistin-sparing strategies 
(Gajdács 2020). A similar study was performed in Turkey, 
where n=243 isolates were assessed by phenotypic and 
molecular methods: in this report, carbapenemase-pro-
ducing isolates were not detected, while overexpression of 
MexAB-OprM (60.9%) and MexXY-OprM (68.8%) efflux 
pumps and decreased permeability due to OprD-related 
porin deficiency (68.8%) were the principal mechanisms 
of resistance (Khalili et al. 2019).
Due to the disadvantageous developments in antibiotic 
resistance trends globally (and the increasing prevalence 
of CRPA), it has been suggested that alternative antimi-
crobial therapeutic strategies should be explored more 
extensively (Hauser et al. 2016; Usai et al. 2019). These 
strategies may include physico-chemical modalities, 
such as sonobactericide (ultrasound), lasers and the use 
of photosensitizers for photodynamic therapy (Lattwein 
et al. 2020; Stájer et al. 2020); in contrast, novel pharma-
cological modalities include bacteriophages, probiotics, 
antimicrobial peptides, antibodies and antivirulence 
compounds, many of which were already included in 
some human clinical trials (Ghosh et al. 2019; Kumar et 
al. 2021). Compounds of natural origin have long been 
proposed as a potential source of novel antimicrobials 
for the treatment of drug resistant infections (either as 
monotherapy or as adjuvant), including MDR Pseudomonas 
(Ding et al. 2021; Amorese et al. 2018). These may include 
extracts of various plant materials, new bioactive com-
pounds or phytopharmaceuticals and essential oils (Le NT 
et al. 2020); these compounds are often characterized by 
good safety and tolerability in vivo, in addition to having 
established indications in ethnopharmacology/traditional 
medicine (Le et al. 2020; Mazzarello et al. 2020). It may 
be assumed that – in addition to novel antibiotics – the 
introduction of such alternative treatments to the clinical 
practice may have a pronounced role in the treatment of 
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